Abstract
Vascular embolisation agents are particles or fluids that can be released into the bloodstream through a catheter to mechanically and/or biologically occlude the target vessel, either temporarily or permanently. This definition excludes vessel-blocking agents or devices such as balloons and coils, which are positioned at the target site, as opposed to released in the bloodstream. Vascular embolisation agents are available as solids, liquids and suspensions. Careful selection of the agent based on the size and calibre of the target vessel ensures that the occlusion is confined to the desired site. In this review, we discuss the 2 main categories of embolisation agents: particles (either non-spherical or microspherical), which are the most widely used; and liquids (glues, gels, sclerosing agents and viscous emulsions). For each agent, we review the characteristics, mechanisms of action, main indications and modalities of use, advantages and drawbacks. The use of embolisation in clinical practice requires a thorough understanding of the behaviour (rheology and vascular topology) and biocompatibility of each agent. To improve the accuracy of targeting, we need new, more sophisticated, bioactive agents, which are being developed.
Keywords: Interventional radiology, endovascular embolisation, occluding agents, resorbable embolic material, particles, surgical glue
Current Vascular Pharmacology
Title: Endovascular Therapeutic Embolisation: An Overview of Occluding Agents and their Effects on Embolised Tissues
Volume: 7 Issue: 2
Author(s): Romaric Loffroy, Boris Guiu, Jean-Pierre Cercueil and Denis Krause
Affiliation:
Keywords: Interventional radiology, endovascular embolisation, occluding agents, resorbable embolic material, particles, surgical glue
Abstract: Vascular embolisation agents are particles or fluids that can be released into the bloodstream through a catheter to mechanically and/or biologically occlude the target vessel, either temporarily or permanently. This definition excludes vessel-blocking agents or devices such as balloons and coils, which are positioned at the target site, as opposed to released in the bloodstream. Vascular embolisation agents are available as solids, liquids and suspensions. Careful selection of the agent based on the size and calibre of the target vessel ensures that the occlusion is confined to the desired site. In this review, we discuss the 2 main categories of embolisation agents: particles (either non-spherical or microspherical), which are the most widely used; and liquids (glues, gels, sclerosing agents and viscous emulsions). For each agent, we review the characteristics, mechanisms of action, main indications and modalities of use, advantages and drawbacks. The use of embolisation in clinical practice requires a thorough understanding of the behaviour (rheology and vascular topology) and biocompatibility of each agent. To improve the accuracy of targeting, we need new, more sophisticated, bioactive agents, which are being developed.
Export Options
About this article
Cite this article as:
Loffroy Romaric, Guiu Boris, Cercueil Jean-Pierre and Krause Denis, Endovascular Therapeutic Embolisation: An Overview of Occluding Agents and their Effects on Embolised Tissues, Current Vascular Pharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157016109787455617
DOI https://dx.doi.org/10.2174/157016109787455617 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and Asthma: Scientific Promise and Clinical Reality
Current Respiratory Medicine Reviews Ventilatory Support in Persistent Pulmonary Hypertension of the Newborn
Current Respiratory Medicine Reviews The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies
Current Neuropharmacology Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Therapeutic Potential of Natural Compounds that Regulate the Activity of Protein Kinase C
Current Medicinal Chemistry Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy
Current Pharmaceutical Biotechnology Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design The Relationship Between Cleft Lip, Maxillary Hypoplasia, Hypoxia and Phenytoin
Current Pharmaceutical Design The Emerging Role of Stereotactic Radiosurgery in the Treatment of Glioblastoma Multiforme
Current Radiopharmaceuticals Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design bmp3 is Required for Integrity of Blood Brain Barrier by Promoting Pericyte Coverage in Zebrafish Embryos
Current Molecular Medicine Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Adipose Derived Stem Cells for Musculoskeletal Regeneration: Recent Patents and Future Perspectives
Recent Patents on Regenerative Medicine Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets